Enliven Therapeutics (ELVN)
Market Price (11/18/2026): $46.82 | Market Cap: $3.4 BilSector: Health Care | Industry: Biotechnology
Enliven Therapeutics (ELVN)
Market Price (11/18/2026): $46.82Market Cap: $3.4 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -135 Mil Stock price has recently run up significantly12M Rtn12 month market price return is 115% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1% Key risksELVN key risks include [1] intense competition for its lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -135 Mil |
| Stock price has recently run up significantly12M Rtn12 month market price return is 115% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1% |
| Key risksELVN key risks include [1] intense competition for its lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nov 12: down 5.6% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved down on the day.
Up 38.1% from its Oct 16 low to Nov 9, down 9.1% since (S&P 500 down 1.4%)
The stock gained across the period, driven by days without company news and a positive Q3 business update. Major increases included October 20 without news, November 4 with broader market sentiment, and November 6 due to its business update.
Nov 6: up 10.4% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose following the Q3 2026 financial results and business update. News of FDA alignment on the ENABLE-2 pivotal Phase 3 trial design and a strong balance sheet drove the increase.
Nov 12: down 5.6% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved down on the day.
Up 38.1% from its Oct 16 low to Nov 9, down 9.1% since (S&P 500 down 1.4%)
The stock gained across the period, driven by days without company news and a positive Q3 business update. Major increases included October 20 without news, November 4 with broader market sentiment, and November 6 due to its business update.
Nov 6: up 10.4% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose following the Q3 2026 financial results and business update. News of FDA alignment on the ENABLE-2 pivotal Phase 3 trial design and a strong balance sheet drove the increase.
Show less
Stock Movement Drivers
Fundamental Drivers
The -14.5% change in ELVN stock from 7/31/2026 to 11/17/2026 was primarily driven by a -19.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312026 | 11172026 | Change |
|---|---|---|---|
| Stock Price ($) | 54.81 | 46.85 | -14.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 63 | 78 | -19.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2026 to 11/17/2026| Return | Correlation | |
|---|---|---|
| ELVN | -14.5% | |
| Market (SPY) | -1.7% | 45.0% |
| Sector (XLV) | 14.4% | 26.1% |
Fundamental Drivers
The 13.6% change in ELVN stock from 4/30/2026 to 11/17/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 11172026 | Change |
|---|---|---|---|
| Stock Price ($) | 41.23 | 46.85 | 13.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 62 | 78 | -20.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 11/17/2026| Return | Correlation | |
|---|---|---|
| ELVN | 13.6% | |
| Market (SPY) | 2.4% | 25.4% |
| Sector (XLV) | 27.9% | 21.2% |
Fundamental Drivers
The 100.0% change in ELVN stock from 10/31/2025 to 11/17/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 11172026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.42 | 46.85 | 100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 52 | 78 | -33.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 11/17/2026| Return | Correlation | |
|---|---|---|
| ELVN | 100.0% | |
| Market (SPY) | 8.5% | 20.0% |
| Sector (XLV) | 30.6% | 13.2% |
Fundamental Drivers
The 278.1% change in ELVN stock from 10/31/2023 to 11/17/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312023 | 11172026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.39 | 46.85 | 278.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 41 | 78 | -47.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2023 to 11/17/2026| Return | Correlation | |
|---|---|---|
| ELVN | 278.1% | |
| Market (SPY) | 81.6% | 27.9% |
| Sector (XLV) | 56.4% | 19.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELVN Return | -90% | 82% | 238% | 63% | -32% | 204% | 112% |
| Peers Return | 43% | -20% | 3% | 78% | -33% | -20% | 13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| ELVN Win Rate | 8% | 50% | 42% | 67% | 33% | 73% | |
| Peers Win Rate | 46% | 50% | 46% | 58% | 75% | 32% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| ELVN Max Drawdown | -91% | -59% | -58% | -35% | -39% | -39% | |
| Peers Max Drawdown | -41% | -46% | -34% | -26% | -59% | -52% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ASPE, ATYR, BBTX, CTY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)
How Low Can It Go
| Event | ELVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.9% | -18.8% |
| % Gain to Breakeven | 46.9% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.6% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 99 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.9% | -24.5% |
| % Gain to Breakeven | 143.4% | 32.4% |
| Time to Breakeven | 156 days | 427 days |
In The Past
Enliven Therapeutics's stock fell -31.9% during the 2025 US Tariff Shock. Such a loss loss requires a 46.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ELVN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.9% | -18.8% |
| % Gain to Breakeven | 46.9% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.6% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 99 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -58.9% | -24.5% |
| % Gain to Breakeven | 143.4% | 32.4% |
| Time to Breakeven | 156 days | 427 days |
In The Past
Enliven Therapeutics's stock fell -31.9% during the 2025 US Tariff Shock. Such a loss loss requires a 46.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enliven Therapeutics (ELVN)
Enliven Therapeutics (ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to treat various cancers. Based in Boulder, Colorado, the company aims to create new therapeutic options for patients battling challenging oncological conditions by targeting specific molecular pathways.
The company's core business revolves around its pipeline of small molecule kinase inhibitors, which are its main products under development. Its lead candidate, ELVN-001, is currently in a Phase 1 clinical trial for adults with chronic myeloid leukemia. Another significant pipeline asset is ELVN-002, which has also entered a Phase 1 clinical trial to evaluate its potential in treating people with cancers that harbor an abnormal HER2 gene.
Enliven Therapeutics primarily serves the market of cancer patients, specifically those diagnosed with chronic myeloid leukemia and individuals suffering from cancers characterized by an abnormal HER2 gene. Through its targeted therapies, the company seeks to provide advanced treatment options within these specialized areas of oncology.
```AI Analysis | Feedback
1. The Amgen or AstraZeneca of early-stage cancer drug development.
2. A startup Bristol Myers Squibb or Merck focused on pioneering new cancer therapies.
3. An Eli Lilly or Pfizer that's just starting to build its cancer drug pipeline.
AI Analysis | Feedback
- ELVN-001: A small molecule inhibitor undergoing Phase 1 clinical trials for chronic myeloid leukemia.
- ELVN-002: A small molecule inhibitor in Phase 1 clinical trials for cancers with an abnormal HER2 gene.
AI Analysis | Feedback
Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company. As described, the company is focused on the discovery and development of small molecule inhibitors for cancer, with its lead candidates, ELVN-001 and ELVN-002, currently in Phase 1 clinical trials.
At this stage of development, Enliven Therapeutics does not have commercial products approved for sale. Therefore, the company does not have major customers that purchase its products. Its operations are funded primarily through investments and, potentially, through research collaborations or grants, rather than product sales to other companies or individuals.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
The key risks to Enliven Therapeutics (ELVN) primarily stem from its nature as a clinical-stage biopharmaceutical company focused on drug development.
- Clinical Trial and Regulatory Risk: As a clinical-stage company, Enliven Therapeutics' success is highly dependent on its drug candidates, particularly ELVN-001 and ELVN-002, successfully progressing through clinical trials and ultimately receiving regulatory approval. The company is "heavily dependent on its lead candidate ELVN-001 for BCR-ABL, with significant clinical trial risks and regulatory uncertainties." There is a considerable "risk of failing to demonstrate safety and efficacy of product candidates", and even if trials are successful, there is "regulatory uncertainty" regarding obtaining approvals. This risk is inherent in the biopharmaceutical industry, where drug candidates often fail in various stages of development.
- Financial Sustainability and Need for Additional Funding: Enliven Therapeutics has consistently operated at a loss, with a significant accumulated deficit, reflecting the substantial investments required for pharmaceutical development. "ELVN's financial position reflects substantial investment in R&D, with a need for additional funding to sustain operations." The company's "financial health is a concern, as evidenced by its significant net losses and negative cash flows." To continue advancing its product candidates through clinical trials and toward commercialization, Enliven Therapeutics will likely need to secure additional capital, which could dilute existing shareholders.
- Competition: The pharmaceutical industry is highly competitive, with numerous established companies and emerging biotech firms vying for market share. Enliven Therapeutics "faces competition from companies with greater financial resources and market presence." Competitors could develop more effective or affordable therapies, achieve regulatory approvals more quickly, or establish strong market positions before Enliven Therapeutics can commercialize its own products.
AI Analysis | Feedback
AI Analysis | Feedback
Enliven Therapeutics' main products, ELVN-001 and ELVN-002, target specific cancer markets with the following addressable market sizes:
-
ELVN-001 (Chronic Myeloid Leukemia): The global chronic myeloid leukemia (CML) treatment market was valued at approximately USD 8.59 billion in 2023 and is projected to reach USD 16.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4%. Another estimate for the global CML treatment market indicates a value of USD 8.6 billion in 2023, with a projection to reach USD 14.3 billion by 2033, growing at a CAGR of 5.2%. For the 7 major markets (7MM), which include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, the CML market reached USD 5.7 billion in 2024 and is expected to grow to USD 8.9 billion by 2035.
-
ELVN-002 (Cancers harboring an abnormal HER2 gene): This product targets HER2+ and HER2 mutant tumors, including HER2-positive breast cancer and HER2+ gastric cancer.
- For the global HER2-positive breast cancer treatment market, it was valued at USD 10.95 billion in 2025 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 3.92%. The 7 major markets (7MM) for metastatic HER2-Positive breast cancer were valued at USD 2,711.6 million in 2024 and are anticipated to reach USD 3,108.1 million by 2035.
- For HER2+ gastric cancer (including GEJ) in the 7 major markets (7MM), the total market size was approximately USD 700 million in 2024 and is projected to increase through 2034.
AI Analysis | Feedback
Enliven Therapeutics (ELVN), a clinical-stage biopharmaceutical company, is focused on the discovery and development of small molecule inhibitors for cancer. Given its current stage of development, expected revenue growth over the next 2-3 years will primarily be driven by key pipeline advancements and strategic activities rather than product sales.
Here are 3-5 expected drivers of Enliven Therapeutics' future revenue growth:
- Advancement of ELVN-001 through pivotal clinical trials: A significant driver for future revenue growth is the successful progression and initiation of the Phase 3 ENABLE-2 pivotal trial for ELVN-001 in chronic myeloid leukemia (CML), which is planned for the second half of 2026. Positive initial Phase 1b data for ELVN-001 has already been reported, and continued successful clinical development will be critical to its potential commercialization.
- Positive clinical data readouts for ELVN-001: Ongoing positive data readouts from the ENABLE trial for ELVN-001 throughout 2026, especially as it advances into later-stage studies, will bolster its market potential and attract further investment or partnerships.
- Strategic partnerships and licensing agreements: As a clinical-stage company, Enliven Therapeutics may generate future revenue through strategic collaborations, licensing agreements, and partnerships. These could include upfront payments, development milestone payments, and future royalties from ELVN-001 or other pipeline candidates. The company is actively evaluating strategic collaborations to accelerate development timelines or maximize commercial value.
- Potential for expedited regulatory pathways and market entry for ELVN-001: ELVN-001 has received Orphan Drug Designation for CML, and the company intends to engage with regulatory authorities to discuss potential expedited approval pathways. A faster path to market, should the clinical data support it and regulators agree, would accelerate the timeline for commercialization and subsequent revenue generation.
AI Analysis | Feedback
Share Issuance
- Enliven Therapeutics completed a $200 million equity raise in June 2025, which included the sale of new shares and warrants.
- A stock sale in 2025 grossed approximately $230 million in proceeds, contributing to the company's cash reserves.
- The weighted-average shares outstanding, basic and diluted, increased from 49.858 million in the fourth quarter of 2024 to 62.213 million in the fourth quarter of 2025.
Inbound Investments
- Enliven Therapeutics closed a $200 million equity raise in June 2025.
- In August 2024, the company received a $10 million milestone payment from Cardurion as per an asset purchase agreement established prior to the merger between Imara Inc. and Enliven Inc.
Capital Expenditures
- While specific capital expenditure figures for property, plant, and equipment are not detailed, the company's significant investment is in research and development.
- Research and development expenses for the full year 2025 totaled $85.9 million, an increase from $80.8 million in 2024 and $64.6 million in 2023.
- These expenses are primarily focused on advancing its pipeline of small molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for cancers with an abnormal HER2 gene.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 5 | 16.4% | 84.2% | 198.3% | CAH 522% · MCK 400% · COR 198% |
| Health Care Services | 20 | 31.2% | 20.2% | 12.4% | RDNT 150% · HIMS 116% · DGX 91% |
| Managed Health Care | 8 | 76.8% | -0.8% | 0.8% | OSCR 155% · HQY 56% · ELV 9% |
| Health Care Facilities | 26 | 17.8% | 19.4% | -9.2% | THC 258% · NHC 231% · EHC 186% |
| Health Care Equipment | 49 | -1.7% | 4.4% | -20.2% | GKOS 390% · UFPT 359% · TMDX 293% |
| Health Care Supplies | 11 | 24.0% | 1.1% | -40.5% | LNTH 248% · HAE 108% · MMSI 25% |
| Pharmaceuticals | 60 | -18.7% | 1.7% | -45.2% | LQDA 1123% · KNSA 638% · XERS 586% |
| Life Sciences Tools & Services | 110 | -22.4% | -26.1% | -76.2% | AXGN 400% · MEDP 187% · NTRA 156% |
| Health Care Technology | 23 | -23.5% | -59.7% | -83.4% | VEEV -8% · DOCS -55% |
| Biotechnology ← | 370 | -33.7% | -38.5% | -83.9% | ELVN 1378% · TRVI 1175% · DNTH 1141% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.95 |
| Mkt Cap | 69.0 |
| Rev LTM | 0 |
| Op Inc LTM | -56 |
| FCF LTM | -44 |
| FCF 3Y Avg | -58 |
| CFO LTM | -44 |
| CFO 3Y Avg | -58 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -44.8% |
| Rev Chg 3Y Avg | -31.0% |
| Rev Chg Q | -44.1% |
| QoQ Delta Rev Chg LTM | -48.6% |
| Op Inc Chg LTM | 28.9% |
| Op Inc Chg 3Y Avg | -10.6% |
| Op Mgn LTM | 33.1% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | -4.8% |
| CFO/Rev LTM | 28.5% |
| CFO/Rev 3Y Avg | 17.4% |
| FCF/Rev LTM | 24.7% |
| FCF/Rev 3Y Avg | 13.5% |
Price Behavior
| Market Price | $46.85 | |
| Market Cap ($ Bil) | 3.7 | |
| First Trading Date | 03/12/2020 | |
| Distance from 52W High | -23.4% | |
| 50 Days | 200 Days | |
| DMA Price | $45.95 | $44.03 |
| DMA Trend | down | up |
| Distance from DMA | 2.0% | 6.4% |
| 3M | 1YR | |
| Volatility | 49.2% | 77.7% |
| Downside Capture | 230.81 | 116.24 |
| Upside Capture | 162.59 | 193.03 |
| Correlation (S&P 500) | 40.5% | 20.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.39 | 1.12 | 1.45 | 0.69 | 1.05 | 1.37 |
| Up Beta | -5.73 | -2.28 | 1.52 | 1.37 | 1.76 | 1.22 |
| Down Beta | 0.14 | 0.03 | 0.16 | -0.71 | 1.00 | 1.17 |
| Up Capture | 211% | 104% | 120% | 97% | 131% | 612% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 11 | 18 | 29 | 61 | 124 | 365 |
| Down Capture | 220% | 264% | 226% | 96% | 62% | 109% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 11 | 25 | 35 | 65 | 127 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | 112.9% | 77.7% | 1.26 | - |
| Sector ETF (XLV) | 24.2% | 16.9% | 1.10 | 13.2% |
| Equity (SPY) | 10.2% | 13.8% | 0.45 | 19.7% |
| Gold (GLD) | -6.3% | 28.8% | -0.23 | 4.7% |
| Commodities (DBC) | 31.6% | 21.3% | 1.18 | -9.8% |
| Real Estate (VNQ) | 10.0% | 14.2% | 0.42 | 19.9% |
| Bitcoin (BTCUSD) | -31.4% | 43.7% | -0.75 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | 23.7% | 84.9% | 0.59 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 17.4% |
| Equity (SPY) | 10.9% | 17.3% | 0.46 | 22.6% |
| Gold (GLD) | 15.5% | 19.2% | 0.65 | 5.5% |
| Commodities (DBC) | 7.1% | 19.6% | 0.25 | 1.9% |
| Real Estate (VNQ) | 0.9% | 19.0% | -0.06 | 19.5% |
| Bitcoin (BTCUSD) | -0.6% | 51.4% | 0.17 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELVN | |
|---|---|---|---|---|
| ELVN | -2.8% | 85.9% | 0.32 | - |
| Sector ETF (XLV) | 12.4% | 16.8% | 0.61 | 13.3% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 17.5% |
| Gold (GLD) | 11.2% | 16.6% | 0.55 | 4.5% |
| Commodities (DBC) | 7.4% | 18.2% | 0.32 | 3.8% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 14.5% |
| Bitcoin (BTCUSD) | 57.2% | 66.3% | 0.97 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 11/16/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2026 | 10.4% | 7.9% | |
| 8/5/2026 | 1.0% | -3.0% | -0.1% |
| 5/7/2026 | 1.1% | 6.9% | -16.5% |
| 3/3/2026 | 4.3% | 5.2% | 31.4% |
| 11/12/2025 | -0.1% | 8.9% | -15.4% |
| 8/13/2025 | -1.1% | -1.6% | -0.1% |
| 5/14/2025 | -10.4% | -14.9% | 10.2% |
| 3/13/2025 | 2.2% | 3.1% | -18.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 7 |
| # Negative | 8 | 10 | 13 |
| Median Positive | 2.2% | 7.9% | 27.1% |
| Median Negative | -1.8% | -5.6% | -14.5% |
| Max Positive | 10.4% | 56.5% | 72.8% |
| Max Negative | -19.0% | -21.4% | -35.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2026 | 10.4% | 7.9% | |
| 8/5/2026 | 1.0% | -3.0% | -0.1% |
| 5/7/2026 | 1.1% | 6.9% | -16.5% |
| 3/3/2026 | 4.3% | 5.2% | 31.4% |
| 11/12/2025 | -0.1% | 8.9% | -15.4% |
| 8/13/2025 | -1.1% | -1.6% | -0.1% |
| 5/14/2025 | -10.4% | -14.9% | 10.2% |
| 3/13/2025 | 2.2% | 3.1% | -18.6% |
| 11/13/2024 | -3.4% | -1.4% | -10.3% |
| 8/13/2024 | 1.3% | 3.6% | 3.8% |
| 5/14/2024 | 0.5% | -4.1% | -7.8% |
| 3/14/2024 | 3.7% | 56.5% | 72.8% |
| 11/9/2023 | -1.5% | -9.8% | -5.9% |
| 8/10/2023 | 0.1% | -7.2% | -4.9% |
| 5/11/2023 | 1.6% | 5.0% | 7.9% |
| 3/15/2022 | 9.7% | 41.0% | -31.2% |
| 11/9/2021 | 5.4% | -3.2% | -21.6% |
| 8/6/2021 | -1.5% | -21.4% | -14.5% |
| 5/11/2021 | 7.3% | 15.8% | 27.1% |
| 3/5/2021 | -19.0% | -18.0% | -35.1% |
| 11/5/2020 | -2.1% | 18.2% | 57.0% |
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 7 |
| # Negative | 8 | 10 | 13 |
| Median Positive | 2.2% | 7.9% | 27.1% |
| Median Negative | -1.8% | -5.6% | -14.5% |
| Max Positive | 10.4% | 56.5% | 72.8% |
| Max Negative | -19.0% | -21.4% | -35.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/05/2026 | 10-Q |
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/05/2026 | 10-Q |
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
Insider Activity
Updated 11/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 10212026 | 38.48 | 6,018 | 231,546 | 1,462,069 | Form |
| 2 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 10212026 | 38.47 | 5,000 | 192,342 | 961,710 | Form |
| 3 | Garland, J. Scott | Direct | Sell | 10052026 | 46.67 | 13,000 | Form | |||
| 4 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 9212026 | 50.35 | 6,018 | 303,003 | 1,913,279 | Form |
| 5 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 9212026 | 50.35 | 5,000 | 251,754 | 1,258,769 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 10212026 | 38.48 | 6,018 | 231,546 | 1,462,069 | Form |
| 2 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 10212026 | 38.47 | 5,000 | 192,342 | 961,710 | Form |
| 3 | Garland, J. Scott | Direct | Sell | 10052026 | 46.67 | 13,000 | Form | |||
| 4 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 9212026 | 50.35 | 6,018 | 303,003 | 1,913,279 | Form |
| 5 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 9212026 | 50.35 | 5,000 | 251,754 | 1,258,769 | Form |
| 6 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 8192026 | 58.58 | 6,018 | 352,551 | 2,345,420 | Form |
| 7 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 8192026 | 58.59 | 5,000 | 292,931 | 1,464,654 | Form |
| 8 | Derynck, Mika K | Direct | Sell | 8062026 | 60.21 | 158,795 | Form | |||
| 9 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 7212026 | 52.64 | 6,018 | 316,780 | 2,424,228 | Form |
| 10 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 7212026 | 52.67 | 5,000 | 263,373 | 1,316,867 | Form |
| 11 | Kunkel, Lori Anne | Direct | Sell | 7082026 | 50.49 | 10,000 | 504,903 | 2,114,737 | Form | |
| 12 | Orbimed, Advisors Llc | See Footnotes | Sell | 6222026 | 45.36 | 860,123 | 39,014,046 | 9,951,922 | Form | |
| 13 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 6222026 | 43.80 | 6,018 | 263,577 | 2,233,706 | Form |
| 14 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 6222026 | 43.80 | 5,000 | 219,017 | 1,095,084 | Form |
| 15 | Orbimed, Advisors Llc | See Footnotes | Sell | 6172026 | 45.02 | 281,408 | 12,668,988 | 11,062,675 | Form | |
| 16 | Kunkel, Lori Anne | Direct | Sell | 6092026 | 34.54 | 10,000 | 345,351 | 1,791,821 | Form | |
| 17 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 5202026 | 39.79 | 5,000 | 198,971 | 994,857 | Form |
| 18 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 4212026 | 47.67 | 5,000 | 238,352 | 1,191,762 | Form |
| 19 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 3272026 | 35.10 | 40,000 | 1,404,024 | 877,515 | Form |
| 20 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 3192026 | 27.76 | 5,000 | 138,800 | 694,000 | Form |
| 21 | Hohl, Benjamin | CHIEF FINANCIAL OFFICER | Direct | Sell | 3102026 | 29.58 | 10,000 | 295,839 | 1,508,779 | Form |
| 22 | Collins, Helen Louise | CHIEF MEDICAL OFFICER | Direct | Sell | 2192026 | 26.17 | 45,000 | 1,177,862 | 654,368 | Form |
| 23 | Heyman, Richard A | See footnote | Sell | 2192026 | 26.18 | 1,230 | 32,196 | 592,806 | Form | |
| 24 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 2102026 | 29.04 | 5,000 | 145,219 | 21,497,872 | Form |
| 25 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 1222026 | 26.75 | 20,000 | 535,099 | 19,937,467 | Form |
| 26 | Heyman, Richard A | See footnote | Sell | 1222026 | 26.75 | 1,230 | 32,902 | 638,691 | Form | |
| 27 | Patel, Anish | CHIEF OPERATING OFFICER | See footnote | Sell | 1132026 | 27.99 | 48,300 | 1,351,762 | 6,017,469 | Form |
| 28 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 1122026 | 27.22 | 91,198 | 2,482,578 | 20,829,832 | Form |
| 29 | Heyman, Richard A | See footnote | Sell | 1122026 | 25.00 | 4,285 | 107,125 | 627,678 | Form | |
| 30 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 1122026 | 24.05 | 41,302 | 993,436 | 20,598,627 | Form |
| 31 | Heyman, Richard A | See footnote | Sell | 1122026 | 25.03 | 9,635 | 241,156 | 639,369 | Form | |
| 32 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 12232025 | 16.84 | 5,000 | 84,206 | 15,118,143 | Form |
| 33 | Patel, Anish | CHIEF OPERATING OFFICER | See footnote | Sell | 12102025 | 21.02 | 6,663 | 140,073 | 5,535,453 | Form |
| 34 | Lyssikatos, Joseph P | CHIEF SCIENTIFIC OFFICER | See footnote | Sell | 11212025 | 22.33 | 12,500 | 279,155 | 20,159,174 | Form |
| 35 | Kintz, Samuel | PRESIDENT AND CEO | See footnote | Sell | 11192025 | 21.82 | 12,500 | 272,739 | 19,427,552 | Form |
| 36 | Patel, Anish | CHIEF OPERATING OFFICER | See footnote | Sell | 11122025 | 17.40 | 6,667 | 116,034 | 4,698,696 | Form |
Investor Activity (13F)
Updated Nov 18, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | $128.4 Mil | 7.4% | 36 | TRIM -30.2% | 13F |
| Fairmount Funds Management LLC | $72.7 Mil | 5.3% | 12 | TRIM -50.0% | 13F |
| Jones Hill Capital LP | $23.2 Mil | 5.0% | 26 | New | 13F |
| Novo Holdings A/S | $50.2 Mil | 4.1% | 22 | TRIM -13.5% | 13F |
| Avidity Partners Management LP | $15.7 Mil | 3.2% | 45 | ADD +185.1% | 13F |
| Spruce Street Capital LP | $12.9 Mil | 3.1% | 28 | TRIM -26.2% | 13F |
| First Turn Management, LLC | $24.5 Mil | 2.7% | 33 | New | 13F |
| Venrock Adviser, LLC | $67.7 Mil | 2.5% | 33 | TRIM -46.5% | 13F |
| Patient Square Capital LP | $7.8 Mil | 1.4% | 29 | TRIM -35.1% | 13F |
| First Light Asset Management, LLC | $7.9 Mil | 0.7% | 35 | New | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| 5AM Venture Management, LLC | $11.9 Mil | 3.7% | 21 | Exited | Dec 31, 2025 | 13F |
| Fairmount Funds Management LLC | $72.7 Mil | 5.3% | 12 | TRIM -50.0% | Mar 31, 2026 | 13F |
| Venrock Adviser, LLC | $67.7 Mil | 2.5% | 33 | TRIM -46.5% | Mar 31, 2026 | 13F |
| Patient Square Capital LP | $7.8 Mil | 1.4% | 29 | TRIM -35.1% | Mar 31, 2026 | 13F |
| Commodore Capital LP | $128.4 Mil | 7.4% | 36 | TRIM -30.2% | Mar 31, 2026 | 13F |
| Spruce Street Capital LP | $12.9 Mil | 3.1% | 28 | TRIM -26.2% | Mar 31, 2026 | 13F |
| Novo Holdings A/S | $50.2 Mil | 4.1% | 22 | TRIM -13.5% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | $128.4 Mil | 7.4% | 36 | TRIM -30.2% | 13F |
| Fairmount Funds Management LLC | $72.7 Mil | 5.3% | 12 | TRIM -50.0% | 13F |
| Venrock Adviser, LLC | $67.7 Mil | 2.5% | 33 | TRIM -46.5% | 13F |
| Novo Holdings A/S | $50.2 Mil | 4.1% | 22 | TRIM -13.5% | 13F |
| First Turn Management, LLC | $24.5 Mil | 2.7% | 33 | New | 13F |
| Jones Hill Capital LP | $23.2 Mil | 5.0% | 26 | New | 13F |
| Avidity Partners Management LP | $15.7 Mil | 3.2% | 45 | ADD +185.1% | 13F |
| Spruce Street Capital LP | $12.9 Mil | 3.1% | 28 | TRIM -26.2% | 13F |
| First Light Asset Management, LLC | $7.9 Mil | 0.7% | 35 | New | 13F |
| Patient Square Capital LP | $7.8 Mil | 1.4% | 29 | TRIM -35.1% | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.